Zealand Pharma A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZLDPF research report →
About the company
Based in Copenhagen, Denmark, Zealand Pharma A/S operates as a biotechnology company dedicated to the entire lifecycle of peptide-based medicines – from their initial discovery and development through to their ultimate commercialization. Its therapeutic portfolio primarily targets gastrointestinal and metabolic disorders, alongside other specialized conditions where existing treatments are insufficient. Currently, Zealand Pharma offers lixisenatide, marketed as Adlyxin and Lyxumia.
- CEO
- Adam Sinding Steensberg
- IPO
- 2013
- Employees
- 385
- HQ
- Copenhagen, DK
Price Chart
- Market Cap
- $3.32B
- P/E
- 3.34
- P/S
- 2.31
- P/B
- 1.47
- EV/EBITDA
- 2.66
- Div Yield
- 0.00%
- Gross Margin
- 99.72%
- Op Margin
- 73.88%
- Net Margin
- 69.22%
- ROE
- 42.59%
- ROIC
- 42.14%
- Revenue
- $9.19B · 14565.56%
- Net Income
- $6.44B · 696.98%
- EPS
- $91.38 · 662.68%
- Op Income
- $7.14B
- FCF YoY
- 786.87%
- 52W High
- $83.12
- 52W Low
- $35.93
- 50D MA
- $47.20
- 200D MA
- $60.56
- Beta
- 0.59
- Avg Volume
- 1.21K
Get TickerSpark's AI analysis on ZLDPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ZLDPF coverage
Recent articles, reports, and earnings notes.
No research on ZLDPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZLDPF report →Similar companies
Peers in the same neighborhood.